Arcturus Therapeutics Holdings Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q2 2024.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $9.42M, a 12.4% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $37.6M, a 15.6% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2023 was $34.6M, a 13.2% increase from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2022 was $30.6M, a 5.87% increase from 2021.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2021 was $28.9M, a 327% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $37.6M $9.42M +$1.04M +12.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $36.6M $10.1M +$1.91M +23.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $34.6M $8.82M +$2.29M +35% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $32.4M $9.27M -$167K -1.77% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $32.5M $8.38M +$1.11M +15.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $31.4M $8.18M +$811K +11% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $30.6M $6.53M -$988K -13.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $31.6M $9.44M +$2.57M +37.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $29M $7.27M -$266K -3.53% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $29.3M $7.37M +$384K +5.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $28.9M $7.52M +$4.69M +166% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $24.2M $6.87M +$4.88M +246% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $19.3M $7.54M +$6.44M +585% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $12.9M $6.99M +$6.14M +723% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $6.76M $2.83M +$2.03M +255% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $4.74M $1.99M +$1.61M +419% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $3.13M $1.1M +$698K +173% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $2.43M $849K +$450K +113% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.98M $797K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $383K -$204K -34.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $403K +$263K +188% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $399K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q3 2018 $587K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $140K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.